Recent Finacing
Recent Raise
Sonoma Biotherapeutics develops genome-edited, antigen-targeted regulatory T-cell (Treg) therapies and a Teff-conditioning biologic, integrating R&D, genetic engineering, manufacturing, and clinical development for autoimmune and degenerative diseases.
